Your browser doesn't support javascript.
loading
Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.
Yang, Dae Sik; Park, Sunmin; Rim, Chai Hong; Yoon, Won Sup; Shin, In-Soo; Lee, Han Ah.
Afiliación
  • Yang DS; Department of Radiation Oncology, Korea University Medical College, Seoul 02841, Korea.
  • Park S; Department of Radiation Oncology, Korea University Guro Hospital, Seoul 08308, Korea.
  • Rim CH; Department of Radiation Oncology, Korea University Ansan Hospital, Ansan 15355, Korea.
  • Yoon WS; Department of Radiation Oncology, Korea University Medical College, Seoul 02841, Korea.
  • Shin IS; Department of Radiation Oncology, Korea University Ansan Hospital, Ansan 15355, Korea.
  • Lee HA; Department of Radiation Oncology, Korea University Medical College, Seoul 02841, Korea.
Medicina (Kaunas) ; 57(10)2021 09 22.
Article en En | MEDLINE | ID: mdl-34684036
ABSTRACT
Background and

objective:

Although transarterial chemoembolization (TACE) has been the commonest local modality for hepatocellular carcinoma (HCC), incomplete repsonse occurs especially for tumors with a large size or difficult tumor accessment. The present meta-analysis assessed the efficacy and feasibility of external beam radiotherapy (EBRT) as a salvage modality after incomplete TACE. Materials and

Methods:

We systematically searched the PubMed, Embase, Medline, and Cochrane databases. The primary endpoint was overall survival (OS), and the secondary endpoints included the response ratem toxicity of grade 3, and local control.

Results:

Twelve studies involving 757 patients were included; the median of portal vein thrombosis rate was 25%, and the pooled median of tumor size was 5.8 cm. The median prescribed dose ranged from 37.3 to 150 Gy (pooled median 54 Gy in *EQD2). The pooled one- and two-year OS rates were 72.3% (95% confidence interval (CI) 60.2-81.9%) and 50.5% (95% CI 35.6-65.4%), respectively; the pooled response and local control rates were 72.2% (95% CI 65.4-78.1%) and 86.6 (95% CI 80.1-91.2%) respectively. The pooled rates of grade ≥3 gastrointestinal toxicity, radiation-induced liver disease, hepatotoxicity, and hematotoxicity were 4.1%, 3.5%, 5.7%, and 4.9%, respectively. Local control was not correlated with intrahepatic (p = 0.6341) or extrahepatic recurrences (p = 0.8529) on meta-regression analyses.

Conclusion:

EBRT was feasible and efficient in regard to tumor response and control; after incomplete TACE. Out-field recurrence, despite favorable local control, necessitates the combination of EBRT with systemic treatments. *Equivalent dose in 2 Gy per fraction scheme.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2021 Tipo del documento: Article